financetom
Business
financetom
/
Business
/
New York City pension leader opposes election of Aramco's chief as BlackRock director
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
New York City pension leader opposes election of Aramco's chief as BlackRock director
May 1, 2024 11:51 AM

NEW YORK/BOSTON, May 1 (Reuters) - A pension fund for

New York City employees urged BlackRock's ( BLK ) shareholders

to vote against the election of Saudi Aramco's chief

executive as director, citing potential conflicts of interest

around the asset manager's decarbonizing strategy as well as

human rights concerns.

The world's top asset manager BlackRock ( BLK ) named Amin Nasser,

the chief of the world's largest oil company Saudi Aramco as an

independent director last year.

On Wednesday, the Comptroller of the City of New York Brad

Lander wrote in a securities filing on behalf of the New York

City Employees' Retirement System that BlackRock's ( BLK ) shareholders

should vote against the election of Nasser at BlackRock's ( BLK ) annual

meeting on May 15.

"We believe that potential conflicts of interest compromise

Nasser's ability to provide independent oversight, both in

general, and particularly concerning BlackRock's ( BLK ) decarbonization

strategy," he wrote. BlackRock ( BLK ) manages about $19 billion on

behalf of the New York City Employees' Retirement System, which

has $43 million invested in the asset manager.

Aramco and BlackRock ( BLK ) did not immediately comment.

BlackRock ( BLK ) has a relatively large board with 16 people

currently nominated for election at its shareholder meeting set

for May 15. The company has faced questions over the size of the

board in the past but its directors easily won re-election last

year.

For this year top proxy advisors Institutional Shareholder

Services and Glass Lewis had both recommended votes "for" all of

BlackRock's ( BLK ) nominees, although they suggested investors vote

"against" the pay of CEO Larry Fink over process and performance

concerns.

BlackRock ( BLK ) has been under fire from U.S. Republican

politicians for its concerns about climate change, although it

continues to invest in fossil fuel companies. When Nasser was

first named to the company's board of directors last year it was

seen as possibly dampening the Republican criticism.

"Nasser and BlackRock ( BLK ) have broadly divergent interests with

respect to the need for decarbonization," the New York pension

fund said on Wednesday.

"Nasser has a vested interest in - and is an outspoken vocal

advocate for - the expansion of fossil fuels," which conflicts

with BlackRock's ( BLK ) commitment to reduce greenhouse gas emissions,

it said.

In Wednesday's filing the New York City pension fund said

Nasser could not be seen as genuinely independent of BlackRock ( BLK )

given a 2022 gas pipeline deal which involved the asset manager

and the company, as well as a 2023 bond issuance linked to that

acquisition.

The filing also mentioned human rights concerns, saying oil

giant Saudi Aramco is "implicated in one of the largest alleged

climate-related breaches of international human rights," which

would pose reputation risks for BlackRock ( BLK ) and its shareholders.

It referred to a letter of concern sent by U.N. experts last

year to Aramco saying its expansion of fossil fuel production

and ongoing exploration threatened human rights.

"Considering these factors, Nasser's continued presence on

BlackRock's ( BLK ) Board poses a reputational risk to company culture,

as well as to the Board and shareholders," the filing said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
May 21, 2024
Tuesday, AstraZeneca Plc ( AZN )  announced its ambitious plan to increase its total revenue to $80 billion by 2030, a significant rise from $45.8 billion in 2023.  Substantial expansion in its oncology, biopharmaceuticals, and rare disease portfolios and introducing 20 new medicines by the decade’s end will fuel the growth.  To sustain growth beyond 2030, the company will invest in transformative technologies...
Dye & Durham Commences Substantial Issuer Bid
Dye & Durham Commences Substantial Issuer Bid
May 21, 2024
07:17 AM EDT, 05/21/2024 (MT Newswires) -- Dye & Durham ( DYNDF ) over the holiday weekend said it has initiated a substantial issuer bid to buy back for cancellation up to $185 million of its issued and outstanding 3.75% convertible senior unsecured debentures due March 1, 2026. The offer will expire on June 21, unless extended, varied, or withdrawn....
Sanofi Partners with Microsoft-Backed OpenAI, Formation Bio to Develop Drugs with AI
Sanofi Partners with Microsoft-Backed OpenAI, Formation Bio to Develop Drugs with AI
May 21, 2024
07:17 AM EDT, 05/21/2024 (MT Newswires) -- Sanofi ( SNY ) said Tuesday it will work with AI companies Formation Bio and Microsoft ( MSFT )-backed (MSFT) OpenAI to develop new medicines. Sanofi ( SNY ) said it will provide the two other firms access to its proprietary data to create AI models for pharmaceutical development. Financial details of the...
Healwell AI Subsidiary Partners With Sunnybrook Hospital to Show AI Platform Role in Cancer Staging
Healwell AI Subsidiary Partners With Sunnybrook Hospital to Show AI Platform Role in Cancer Staging
May 21, 2024
07:16 AM EDT, 05/21/2024 (MT Newswires) -- Healwell AI (AIDX.TO), which gained 10% last Friday, said its subsidiary Pentavere Research Group, partnered with Sunnybrook Health Sciences Centre in Toronto and Dr. Tony Eskander, a head and neck surgical oncologist there, to demonstrate how Pentavere's Darwen AI platform can help improve cancer staging to support treatment decisions and improve patient outcomes....
Copyright 2023-2026 - www.financetom.com All Rights Reserved